UNSPSC 51286707: Tetroxoprim

This classification denotes a dihydrofolate reductase inhibitor with the molecular formula C16H22N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5R6712AY0K, chemically known as 2,4-pyrimidinediamine, 5-((3,5-dimethoxy-4-(2-methoxyethoxy)phenyl)methyl)- but more generally known as tetroxoprim, which bears US NIH Compound Identifier 65450. European Medicines Agency schedules Tetroxoprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10953MIG.

The term TETROXOPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 29, No. 10 1975, List 15). TETROXOPRIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

UNSPSC 51286707 Tetroxoprim, a Commodity code, shows limited recent state and local procurement activity. The two most recent opportunities associated with this code do not reflect procurement of tetroxoprim itself; instead, they document pharmaceutical supply contracts for unrelated products—doxycycline and ciprofloxacin in one case, and naloxone and drug deactivation systems in another. The code's nominal scope—a specific antibiotic pharmaceutical—diverges from the actual work being solicited under it in available records, suggesting either classification misalignment or dormant procurement activity for this particular active pharmaceutical ingredient at the state and local level.

The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract to Chartwell Rx LLC on August 28, 2026, through the MMCAP Infuse consortium for doxycycline and ciprofloxacin products totaling $2,999,999.11 over the life of the contract with renewal options. Seminole County, Florida released an IFB on June 30, 2026, for naloxone and safe drug deactivation systems with a response deadline of July 26, 2023. Neither opportunity reflects actual procurement of tetroxoprim. State and local buyers appear to classify pharmaceutical products broadly under related UNSPSC codes, but this Commodity code does not currently map to active solicitations for the specific agent it names. Firms pursuing pharmaceutical supply contracts at the state and local level should monitor broader family-level pharmaceutical codes and cooperative purchasing vehicles for relevant opportunities.